Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn if men with metastatic prostate cancer and rising
Prostate Specific Antigen (PSA), who have been surgically castrated or are undergoing
androgen deprivation with Luteinizing Hormone Releasing Hormone (LHRH) treatment, respond to
dasatinib. The safety of this treatment will also be studied.